<SEC-DOCUMENT>0001213900-25-011304.txt : 20250207
<SEC-HEADER>0001213900-25-011304.hdr.sgml : 20250207
<ACCEPTANCE-DATETIME>20250207160504
ACCESSION NUMBER:		0001213900-25-011304
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250207
DATE AS OF CHANGE:		20250207

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEUROONE MEDICAL TECHNOLOGIES Corp
		CENTRAL INDEX KEY:			0001500198
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				270863354
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40439
		FILM NUMBER:		25601663

	BUSINESS ADDRESS:	
		STREET 1:		7599 ANAGRAM DR
		CITY:			EDEN PRAIRIE
		STATE:			MN
		ZIP:			55344
		BUSINESS PHONE:		(952) 426-1383

	MAIL ADDRESS:	
		STREET 1:		7599 ANAGRAM DR
		CITY:			EDEN PRAIRIE
		STATE:			MN
		ZIP:			55344

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Original Source Entertainment, Inc.
		DATE OF NAME CHANGE:	20100830
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>ea0230318-defa14a_neuroone.htm
<DESCRIPTION>DEFINITIVE ADDITIONAL MATERIALS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 12pt; text-transform: uppercase"><B>Schedule
14A Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Amendment No. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed by the Registrant&emsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed by a Party other than the Registrant&emsp;&thinsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="text-align: justify; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Preliminary Proxy Statement </FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) </FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Definitive Proxy Statement </FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Definitive Additional Materials </FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Soliciting Material under &sect;240.14a-12</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>NeuroOne Medical
Technologies Corporation </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Name of Registrant as Specified in Its Charter)
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Name of Person(s) Filing Proxy Statement, if
other than the Registrant) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Payment of Filing Fee (Check all boxes that apply):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">No fee required. </FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Fee paid previously with preliminary materials </FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>








<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NeuroOne Medical Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">7599 Anagram Dr.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Eden Prairie, MN 55344</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SUPPLEMENT TO THE PROXY STATEMENT DATED JANUARY
21, 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE 2025 ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD FEBRUARY 14, 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">This Second Supplement (this
&ldquo;Supplement&rdquo;), dated February 7, 2025, further supplements the definitive proxy statement on Schedule 14A (the &ldquo;Proxy
Statement&rdquo;) filed by NeuroOne Medical Technologies Corporation, a Delaware corporation, referred to herein as we, us, our or the
Company, with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on January 21, 2025, as supplemented on February 5,
2025, in connection with the solicitation by the Company&rsquo;s Board of Directors (the &ldquo;Board&rdquo;), of proxies to be voted
at the 2025 Annual Meeting of Stockholders, or any adjournment or postponement thereof (the &ldquo;Annual Meeting&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">We are providing this Supplement
to correct the description of what constitutes a quorum for the Annual Meeting. As such, the disclosure included on page 1 of the Proxy
Statement relating to the requirements to obtain a quorum at the Annual Meeting is amended as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 20pt; text-align: justify; text-indent: 0pt">&ldquo;The holders of
one-third of the outstanding shares of stock entitled to vote at the Annual Meeting as of the record date must be present, in person
or by proxy duly authorized at the Annual Meeting in order to hold the Annual Meeting and conduct business. This presence is called
a quorum. Your shares are counted as present at the Annual Meeting if you are present and vote in person at the Annual Meeting or if
you have properly submitted a proxy.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">THIS SUPPLEMENT SHOULD BE READ
IN CONJUNCTION WITH THE PROXY STATEMENT, WHICH CONTAINS IMPORTANT ADDITIONAL INFORMATION. Except as to the matters specifically discussed
herein, this Supplement does not otherwise modify or update any information or disclosure contained in the Proxy Statement. Capitalized
terms used but not otherwise defined in this Supplement shall have the meanings assigned to such terms in the Proxy Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  G .X# 2(  A$! Q$!_\0
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M53VSZ&LS^T/'T@^QC8)/N[P8@WYYHHH V/"O@B73[[^U=7F$][DLJ@[@I/\
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$BW/_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
